Cargando…

The role of ADAMTS‐13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies

ESSENTIALS: Molecular diagnostics has improved the differentiation of acute thrombotic microangiopathys (TMAs). Atypical hemolytic uremic syndrome may have features mimicking thrombotic thrombocytopenic purpura. We identified novel complement mutations and a high incidence of CD46, with favorable lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, E. H., Westwood, J. P., Brocklebank, V., Wong, E. K. S., Tellez, J. O., Marchbank, K. J., McGuckin, S., Gale, D. P., Connolly, J., Goodship, T. H. J., Kavanagh, D., Scully, M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	PLATELETS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737436/ https://www.ncbi.nlm.nih.gov/pubmed/26559391 http://dx.doi.org/10.1111/jth.13189

Ejemplares similares

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014)

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea
por: Brocklebank, Vicky, et al.
Publicado: (2017)

Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience
por: McGuckin, S, et al.
Publicado: (2014)

Enhanced activity of an ADAMTS‐13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke
por: South, K., et al.
Publicado: (2018)

ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies
por: Sarig, Galit
Publicado: (2014)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020)

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
por: Broome, Catherine M., et al.
Publicado: (2022)

Hypothermia‐induced activation of the splenic platelet pool as a risk factor for thrombotic disease in a mouse model
por: Horioka, Kie, et al.
Publicado: (2019)

Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response
por: Pasalic, L., et al.
Publicado: (2018)

Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019
Publicado: (2022)

PPARγ agonists negatively regulate αIIbβ3 integrin outside‐in signaling and platelet function through up‐regulation of protein kinase A activity
por: Unsworth, A. J., et al.
Publicado: (2017)

Complement in Secondary Thrombotic Microangiopathy
por: Palma, Lilian Monteiro Pereira, et al.
Publicado: (2020)

Super‐resolution microscopy as a potential approach to diagnosis of platelet granule disorders
por: Westmoreland, D., et al.
Publicado: (2016)

Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next‐generation sequencing
por: Fidalgo, Teresa, et al.
Publicado: (2017)

Complement, thrombotic microangiopathy and disseminated intravascular coagulation
por: Kurosawa, Shinichiro, et al.
Publicado: (2014)

A humanized monoclonal antibody that inhibits platelet‐surface ERp72 reveals a role for ERp72 in thrombosis
por: Holbrook, L.‐M., et al.
Publicado: (2018)

The chaperone protein HSP47: a platelet collagen binding protein that contributes to thrombosis and hemostasis
por: Sasikumar, P., et al.
Publicado: (2018)

Postsurgical Thrombotic Microangiopathy and Deregulated Complement
por: van Herpt, Thijs T. W., et al.
Publicado: (2022)

Amplification of human platelet activation by surface pannexin-1 channels
por: Taylor, K A, et al.
Publicado: (2014)

Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets
por: Poulter, N. S., et al.
Publicado: (2017)

Thrombotic microangiopathies assessment: mind the complement
por: Blasco, Miquel, et al.
Publicado: (2020)

Akt and mitogen‐activated protein kinase enhance C‐type lectin‐like receptor 2‐mediated platelet activation by inhibition of glycogen synthase kinase 3α/β
por: Moroi, A. J., et al.
Publicado: (2015)

The platelet-surface thiol isomerase enzyme ERp57 modulates platelet function
por: Holbrook, L-M, et al.
Publicado: (2012)

An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy
por: Aigner, Christof, et al.
Publicado: (2019)

Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2
por: HUGHES, C E, et al.
Publicado: (2008)

P1642: OUTCOMES IN HOSPITALIZED PATIENTS WITH COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY
por: Logothetis, C., et al.
Publicado: (2022)

Protein kinase Cε and protein kinase Cθ double-deficient mice have a bleeding diathesis
por: UNSWORTH, A J, et al.
Publicado: (2012)

Platelet endothelial cell adhesion molecule-1 regulates collagen-stimulated platelet function by modulating the association of phosphatidylinositol 3-kinase with Grb-2-associated binding protein-1 and linker for activation of T cells
por: Moraes, L A, et al.
Publicado: (2010)

Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency
por: van Asten, Ivar, et al.
Publicado: (2019)

Manipulating megakaryocytes to manufacture platelets ex vivo
por: Karagiannis, P, et al.
Publicado: (2015)

Platelet collagen receptor Glycoprotein VI‐dimer recognizes fibrinogen and fibrin through their D‐domains, contributing to platelet adhesion and activation during thrombus formation
por: Induruwa, I., et al.
Publicado: (2018)

CLEC‐2‐dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP
por: Borgognone, A., et al.
Publicado: (2014)

Dimeric FcγR ectodomains detect pathogenic anti‐platelet factor 4–heparin antibodies in heparin‐induced thromobocytopenia
por: Wines, B. D., et al.
Publicado: (2018)

Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation
por: Dunster, Joanne L., et al.
Publicado: (2019)

Anti‐GPVI nanobody blocks collagen‐ and atherosclerotic plaque–induced GPVI clustering, signaling, and thrombus formation
por: Jooss, Natalie J., et al.
Publicado: (2022)

Diagnosis and treatment of thrombotic microangiopathy
por: Thompson, Gemma L., et al.
Publicado: (2022)

Localized endothelial‐based control of platelet aggregation and coagulation under flow: A proof‐of‐principle vessel‐on‐a‐chip study
por: Brouns, Sanne L.N., et al.
Publicado: (2020)

Complement Mediated Endothelial Damage in Thrombotic Microangiopathies
por: Blasco, Miquel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k1i5n1eoi1i6q9kvrh0uuaff5o